Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine by CanSino Biologics for Neisseria meningitidis Infections: Likelihood of Approval
Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine is under clinical development by CanSino Biologics and currently in Phase III...
Convidecia by CanSino Biologics for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Convidecia is under clinical development by CanSino Biologics and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to...
Pneumococcal vaccine by CanSino Biologics for Streptococcal Pneumonia: Likelihood of Approval
Pneumococcal vaccine is under clinical development by CanSino Biologics and currently in Phase I for Streptococcal Pneumonia. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of CanSino Biologics's Pneumococcal Vaccine?
Pneumococcal Vaccine is a subunit vaccine commercialized by CanSino Biologics, with a leading Phase I program in Streptococcal Pneumonia. According...